Business
Interim Report January – March 2025
STOCKHOLM, SE / ACCESS Newswire / May 6, 2025 / Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for first quarter ...
About this update from Vicore Pharma Holding Ab
[{"type":"text","content":"STOCKHOLM, SE / ACCESS Newswire / May 6, 2025 / Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for first quarter 2025.","length":267,"tagName":"p"},{"type":"text","content":""As we conclude the first quarter of 2025, I am proud to reflect on Vicore Pharma's focused execution and unwavering commitment to advancing a potentially disease-modifying treatment for IPF. This quarter was a period of operational momentum as we continued to activate sites and enroll patients in our global Phase 2b ASPIRE trial. Our team's dedication to scientific innovation and patient-centric research remains the driving force behind our progress." Ahmed Mousa, CEO","length":491,"tagName":"p"},{"type":"text","content":"Significant events during the first quarter","length":43,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In January, the United States Food and Drug Administration (FDA) granted Fast Track designation (FTD) to buloxibutid, recognizing its disease-modifying potential for the treatment of idiopathic pulmonary fibrosis (IPF).","length":219,"tagName":"p"}]},{"val":[{"type":"text","content":"In March, it was decided that INIM Pharma AB will merge with its parent company, Vicore Pharma Holding AB.","length":106,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":325,"olType":false},{"type":"text","content":"Significant events after the period","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"No significant events occurred after the first quarter.","length":55,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":55,"olType":false},{"type":"text","content":"Financial overview for the period January 1 - March 31, 2025","length":61,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue amounted to SEK 0.9 million and SEK 104.2 million for the three months ended March 31, 2025 and 2024, respectively.","length":123,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating profit/(loss) amounted to (SEK 91.5 million) and SEK 23.2 million for the three months ended March 31, 2025 and 2024, respectively.","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"Profit/(loss) f...